DOP2010000119A - Derivados de tetrazol como moduladores de receptores de glutamato metabotropicos (mglurs) - Google Patents

Derivados de tetrazol como moduladores de receptores de glutamato metabotropicos (mglurs)

Info

Publication number
DOP2010000119A
DOP2010000119A DO2010000119A DO2010000119A DOP2010000119A DO P2010000119 A DOP2010000119 A DO P2010000119A DO 2010000119 A DO2010000119 A DO 2010000119A DO 2010000119 A DO2010000119 A DO 2010000119A DO P2010000119 A DOP2010000119 A DO P2010000119A
Authority
DO
Dominican Republic
Prior art keywords
mglurs
modulators
receivers
metabotropic glutamate
tetrazol
Prior art date
Application number
DO2010000119A
Other languages
English (en)
Spanish (es)
Inventor
Erwan Arzel
Louise Edwards
Methvin Isaac
Donald A Mcleod
Abdelmalik Slassi
Tao Xin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2010000119(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of DOP2010000119A publication Critical patent/DOP2010000119A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DO2010000119A 2007-10-19 2010-04-19 Derivados de tetrazol como moduladores de receptores de glutamato metabotropicos (mglurs) DOP2010000119A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98129407P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
DOP2010000119A true DOP2010000119A (es) 2010-05-31

Family

ID=40567640

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000119A DOP2010000119A (es) 2007-10-19 2010-04-19 Derivados de tetrazol como moduladores de receptores de glutamato metabotropicos (mglurs)

Country Status (21)

Country Link
US (1) US7960422B2 (enExample)
EP (1) EP2231647A4 (enExample)
JP (1) JP2011500673A (enExample)
KR (1) KR20100090777A (enExample)
CN (1) CN101896480A (enExample)
AR (1) AR068921A1 (enExample)
AU (1) AU2008312055A1 (enExample)
BR (1) BRPI0818448A2 (enExample)
CA (1) CA2703425A1 (enExample)
CL (1) CL2008003085A1 (enExample)
CO (1) CO6321281A2 (enExample)
CR (1) CR11376A (enExample)
DO (1) DOP2010000119A (enExample)
EA (1) EA201000654A1 (enExample)
IL (1) IL204958A0 (enExample)
MX (1) MX2010004272A (enExample)
PE (1) PE20090875A1 (enExample)
TW (1) TW200934771A (enExample)
UY (1) UY31403A1 (enExample)
WO (1) WO2009051556A1 (enExample)
ZA (1) ZA201002694B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
MX2010003346A (es) * 2007-10-19 2010-04-09 Boehringer Ingelheim Int Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
WO2009050236A1 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Neue piperazino-dihydrothienopyrimidin-derivate
WO2009050248A1 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Substituierte piperidino-dihydrothienopyrimidine
US8536185B2 (en) * 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
WO2010071559A1 (en) * 2008-12-18 2010-06-24 Astrazeneca Ab Processes for the manufacture of 3-{4-methyl-5- [ (ir) -1- (2- (3-methylphenyl) -2h-tetrazol-5-yl) -ethoxy] -4h- [1,2, 4] triazol-3-yl} -pyridine, 4-methyl-3-methylthio-5- (3- pyridyl)-l,2,4-triazole, and (ir) -1- [2- (3-methylphenyl) -2h- tetrazol-5-yl] ethanol
US8883827B2 (en) 2009-06-05 2014-11-11 Oslo University Hospital Hf Azole derivatives as WTN pathway inhibitors
CN103429583A (zh) 2010-12-08 2013-12-04 奥斯陆大学医院公司 作为wnt信号通路抑制剂的三唑衍生物
MX2013010698A (es) 2011-03-18 2014-02-17 Novartis Ag Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson.
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
CN106032377A (zh) * 2015-03-12 2016-10-19 天津药物研究院有限公司 四氮唑类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663332A (en) * 1985-10-10 1987-05-05 Hoffman-La Roche Inc. 5-substituted N-alkylated tetrazoles
EP0596933A1 (en) 1991-08-03 1994-05-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
DE10023430A1 (de) 2000-05-12 2001-11-15 Bayer Ag Substituierte N-Benzoyl-N'-(tetrazolylphenyl)-harnstoffe
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AU2002341921B2 (en) 2001-10-04 2007-05-31 Merck Sharp & Dohme Corp. Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
WO2003077918A1 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
CN1894241A (zh) * 2002-08-09 2007-01-10 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
EA200601266A1 (ru) * 2004-02-18 2007-02-27 Астразенека Аб Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
JP5084269B2 (ja) 2004-02-18 2012-11-28 アストラゼネカ アクチボラグ テトラゾール化合物及び代謝共役型グルタミン酸受容体アンタゴニストとしてのそれらの使用
JP2007523181A (ja) 2004-02-18 2007-08-16 アストラゼネカ アクチボラグ ポリヘテロ環式化合物、および、代謝型グルタミン酸受容体アンタゴニストとしてのそれらの使用
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
UY29796A1 (es) * 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
TW200811157A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
TW200811156A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators IV

Also Published As

Publication number Publication date
ZA201002694B (en) 2011-03-30
BRPI0818448A2 (pt) 2015-05-12
MX2010004272A (es) 2010-04-30
US20090131454A1 (en) 2009-05-21
CR11376A (es) 2010-07-19
CN101896480A (zh) 2010-11-24
WO2009051556A1 (en) 2009-04-23
CO6321281A2 (es) 2011-09-20
JP2011500673A (ja) 2011-01-06
TW200934771A (en) 2009-08-16
EA201000654A1 (ru) 2010-12-30
UY31403A1 (es) 2009-05-29
AU2008312055A1 (en) 2009-04-23
KR20100090777A (ko) 2010-08-17
US7960422B2 (en) 2011-06-14
EP2231647A1 (en) 2010-09-29
EP2231647A4 (en) 2011-08-31
PE20090875A1 (es) 2009-08-08
AR068921A1 (es) 2009-12-16
CA2703425A1 (en) 2009-04-23
IL204958A0 (en) 2010-11-30
CL2008003085A1 (es) 2009-10-09

Similar Documents

Publication Publication Date Title
DOP2010000119A (es) Derivados de tetrazol como moduladores de receptores de glutamato metabotropicos (mglurs)
ECSP11011066A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1
CU24038B1 (es) Derivados de sulfonamidas útiles para el tratamiento de enfermedades que respondan a los mediadores del receptor cxcr2
BR112012026004A2 (pt) derivados de ariletinila
SV2009003346A (es) Compuestos triciclicos, composiciones y procedimientos.
CR20120327A (es) Moduladores alostéricos positivos de receptores m1 de la quinolina amida
CO6361937A2 (es) Derivados de heteroaril amidas y sus usos como activadores de glucoquinasa
CR20120234A (es) Derivados de sulfonamida heterocíclicos útiles como inhibidores de mek
CR20110057A (es) Proceso para la preparacion de derivados de benzoimidazol-2-il pirimidina
UY33118A (es) Indazoles aminotiazolona sustituidos como moduladores del receptor a relacionado con estrógenos
CR20130431A (es) 5-(fenil)/piridinil-etinil)-2-piridina/ 2-pirimidina-carboxamidas como moduladores de mglur5
AR093042A1 (es) Derivados de etinilo
CO6761304A2 (es) Nuevos compuestos de bezodioxol-piperazina
EA200970662A1 (ru) Трициклические соединения и их применение в качестве модуляторов глюкокортикоидного рецептора
CO6541592A2 (es) Tiazoles biciclicos como moduladores alostericos de receptores de mglur5
CR20150158A (es) Derivados de etinilo como moduladores de receptor de actividad mglur5
CR20150143A (es) Derivados de etinilo como moduladores del receptor de actividad mglur5
CU23983B1 (es) Compuestos de fenantrenona
CU20100070A7 (es) Derivados de tetrazol como moduladores de receptores de glutamato metabotrópicos (mglurs)
DOP2011000197A (es) Derivados de arilciclopropilacetamida utiles como activadores de glucoquinasa
CO6680709A2 (es) Nuevos derivados dihidrobenzoxatiazepinas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY32991A (es) Derivados de dihidro pirroloquinolina
CO6450694A2 (es) Proceso para producir compuesto de acido carboxilico
CL2022002986A1 (es) Compuestos derivados de azetidina-3-ilmetanol como moduladores del receptor ccr6
CL2010001635A1 (es) Derivados de pirimidinas utiles como moduladores del receptor h4; y su procedimiento de preparacion.